
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences has demonstrated a positive growth trajectory with a significant 22% year-over-year increase in its core screening business driven primarily by the Cologuard test, which is expected to continue gaining market share towards its long-term goal of over 40%. The company has raised its 2025 revenue guidance following strong performance, with contributions expected from higher average selling prices of Cologuard Plus and continued adoption of its products, while also making strides towards achieving positive Adjusted EBITDA. With a target to screen at least 30 million people by 2027, a threefold increase from previous levels, and the introduction of a digital marketing campaign for its Cancerguard blood test, Exact Sciences is positioning itself for robust future growth in the oncology diagnostics market.
Bears say
Exact Sciences faces a negative outlook due to its dependence on promotional marketing spending to drive demand for its Cologuard test, indicating a vulnerability in its revenue streams. The company has a history of net losses, raising concerns about its ability to achieve and maintain GAAP profitability in the future. Furthermore, the projected revenue for 2027 of $4.0 billion falls short of expectations, which, combined with the recent downgrades in rating due to the announced acquisition, suggests potential challenges in financial stability and growth.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares